By Don Dion : Recro Pharma Inc. ( REPH ), a clinical stage pharmaceutical firm, developing non-opioid pain therapeutics, plans to raise $28 million in its upcoming IPO this week. The Malvern, Pennsylvania-based firm will offer 2.5 million shares at an expected price range of $10-$12 per share. If
offer to acquire all of the outstanding shares of Cadence ( CADX ) for $14.00 per share. This represents a 32% premium ..... volume weighted average price of $10.62 per share for Cadence Pharmaceuticals , Inc. The transaction is expected to close in mid to late
Top 10 Gainers: OPTT +42% . DHRM +35% . CADX +26% . HNSN +21% . ISSC +22% . PED +18% . CBAK +15% . CAP +16% . STML +15% . SINO +15% . Top 10 Losers: BLOX
Mallinckrodt announced today that is acquiring Cadence Pharmaceuticals for $1.3 billion. The deal gives Mallinckrodt a new platform to build out a hospital-focused pharmaceutical business, but
Mallinckrodt ( MNK ) is +8% and Cadence ( CADX ) +26% following news that Mallinckrodt has agreed to acquire Cadence for $1.3B. The deal will increase Mallinckrodt's
Gainers: CADX +26% . HNSN +14% . RNA +10% . INVN +9% . INO +9% . MNK +8% . S +7% . SBS +5% . Losers: BLOX -43% . NNVC -13% . RAX -12% . DF -10% . BNNY -9% . NMM -6% . CSIQ -6% . CAG -6% . GRPN -5% . Post your comment!
Feb 11 (Reuters) - Specialty pharmaceuticals company Mallinckrodt Plc said it would buy pain drug maker Cadence Pharmaceuticals Inc for about $1.3 billion to expand in the hospital market, where...
Feb 11 (Reuters) - Specialty pharmaceuticals company Mallinckrodt Plc said it would buy Cadence Pharmaceuticals Inc for about $1.3 billion to acquire Cadence's pain drug Ofirmev.
Mallinckrodt ( MNK ) has agreed to acquire Cadence Pharmaceuticals ( CADX ) for $1.3B. Mallinckrodt is offering $14.00 a share, which represents a 32% premium to Cadence's trailing 30-trading
By Smith On Stocks : On January 30, 2014, Cadence ( CADX ) announced that it had entered into a settlement agreement with Sandoz to resolve pending patent litigation in regard to Ofirmev